ChartTrendsÂ®: Multiple Sclerosis Report Reveals the Latest Approach to the Treatment and Management of MS
EXTON, Pa., Nov. 2, 2010 /PRNewswire/ — BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrendsÃ‚®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs).
In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications, prevalence of symptoms and symptomatic treatment), the report provides insight into the factors that drive decisions to initiate treatment and factors that drive DMA brand selection for both first line and switch patients. Profiles for patients treated with each DMA brand (Avonex, Betaseron, Copaxone, Rebif and Tysabri) are provided. There are a number of differences between patients treated with the various DMAs including MRI status, functioning, disease progression, clinical response and likelihood of switching to a pipeline DMA in the future. The most likely patient types for newly approved Gilenya and late-stage DMAs in development (e.g. Movectro, alemtuzumab, daclizumab) are identified. A number of patient characteristics, including disease classification and current DMA brand, influence the likelihood of a potential switch to Gilenya.
Since initiating on their most current DMA, one-third of patients have experienced an exacerbation with the most common symptoms including muscle weakness and gait/coordination issues. While most exacerbations are treated with short steroid pulses, the use of chronic pharmacological treatment is common for management of spasticity, pain syndromes, bladder/bowel dysfunction, depression/apathy and fatigue. The patient types being selected for treatment with Ampyra, the first FDA-approved symptomatic agent for MS launched in March 2010, are identified in the report.
About BioTrends Research Group, Inc.
BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com. BioTrends Research Group, Inc. is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact: BioTrends Research Group, Inc. Decision Resources, Inc. Sharon Funk Christopher Comfort 404-223-2963 781-993-2597 email@example.com firstname.lastname@example.org
SOURCE BioTrends Research Group, Inc.